Evidence map›Paper›PMID 33422598›Full record

Observational studyAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021

The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study.

Dennis G Moledina, Michael Simonov, Yu Yamamoto, Jameel Alausa, Tanima Arora, Aditya Biswas, Lloyd G Cantley, Lama Ghazi, Jason H Greenberg, Monique Hinchcliff and 10 more

Open access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Positive fluid balance is associated with earlier acute kidney injury in COVID-19 patients.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Dennis G MoledinaSection of Nephrology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Clinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Michael SimonovClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Yu YamamotoClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Jameel AlausaClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Tanima AroraClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Aditya BiswasClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Lloyd G CantleySection of Nephrology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Lama GhaziSection of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Jason H GreenbergSection of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Section of Pediatric Nephrology, Department of Pediatrics, Yale School of Medicine, New Haven, CT.
Monique HinchcliffClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Section of Rheumatology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Chenxi HuangCenter for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.
Sherry G MansourSection of Nephrology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Clinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Melissa MartinClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Aldo PeixotoSection of Nephrology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Wade SchulzDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.
Labeebah SubairClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Jeffrey M TestaniSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT.
Ugochukwu UgwuowoClinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Patrick YoungCenter for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.
F Perry WilsonSection of Nephrology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Clinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT. Electronic address: francis.p.wilson@yale.edu.
Yale University · USYale New Haven Hospital · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2008 to 2022
$16.8M
PATHOPHYSIOLOGY OF ACUTE AND CHRONIC RENAL DISEASET32DK007276 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S., CANTLEY, LLOYD G · 1986 to 2022
$9.3M
Macrophage Function in Kidney RepairR01DK093771 · NIDDK · YALE UNIVERSITY · PI LLOYD G CANTLEY · 2012 to 2026
$3.9M
Optimizing Electronic Alerts for Acute Kidney InjuryR01DK113191 · NIDDK · YALE UNIVERSITY · PI WILSON, FRANCIS PERRY · 2018 to 2022
$3.1M
Stem cell population of the renal tubuleR01DK066216 · NIDDK · YALE UNIVERSITY · PI CANTLEY, LLOYD G · 2004 to 2010
$2.0M
Personalized Recommendations for Acute Kidney Injury (AKI) Care Using a Kidney Action Team: A Randomized TrialR01HS027626 · AHRQ · YALE UNIVERSITY · PI WILSON, FRANCIS PERRY · 2021 to 2025
$1.9M
Identification of Non-Invasive Biomarkers and Indices for Diagnosis of Drug-Induced Acute Interstitial NephritisK23DK117065 · NIDDK · YALE UNIVERSITY · PI MOLEDINA, DENNIS G. · 2018 to 2022
$920k
AHRQ HHS R01 HS027626NCATS NIH HHS UL1 TR001863NIDDK NIH HHS K23 DK117065NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK066216NIDDK NIH HHS R01 DK113191NIDDK NIH HHS T32 DK007276
6 · The paper itself

Abstract

RATIONALE &

objectiveAlthough coronavirus disease 2019 (COVID-19) has been associated with acute kidney injury (AKI), it is unclear whether this association is independent of traditional risk factors such as hypotension, nephrotoxin exposure, and inflammation. We tested the independent association of COVID-19 with AKI. STUDY

designMulticenter, observational, cohort study. SETTING &

participantsPatients admitted to 1 of 6 hospitals within the Yale New Haven Health System between March 10, 2020, and August 31, 2020, with results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing via polymerase chain reaction of a nasopharyngeal sample. EXPOSURE: Positive test for SARS-CoV-2. OUTCOME: AKI by KDIGO (Kidney Disease: Improving Global Outcomes) criteria. ANALYTICAL APPROACH: Evaluated the association of COVID-19 with AKI after controlling for time-invariant factors at admission (eg, demographic characteristics, comorbidities) and time-varying factors updated continuously during hospitalization (eg, vital signs, medications, laboratory results, respiratory failure) using time-updated Cox proportional hazard models.

resultsOf the 22,122 patients hospitalized, 2,600 tested positive and 19,522 tested negative for SARS-CoV-2. Compared with patients who tested negative, patients with COVID-19 had more AKI (30.6% vs 18.2%; absolute risk difference, 12.5% [95% CI, 10.6%-14.3%]) and dialysis-requiring AKI (8.5% vs 3.6%) and lower rates of recovery from AKI (58% vs 69.8%). Compared with patients without COVID-19, patients with COVID-19 had higher inflammatory marker levels (C-reactive protein, ferritin) and greater use of vasopressors and diuretic agents. Compared with patients without COVID-19, patients with COVID-19 had a higher rate of AKI in univariable analysis (hazard ratio, 1.84 [95% CI, 1.73-1.95]). In a fully adjusted model controlling for demographic variables, comorbidities, vital signs, medications, and laboratory results, COVID-19 remained associated with a high rate of AKI (adjusted hazard ratio, 1.40 [95% CI, 1.29-1.53]). LIMITATIONS: Possibility of residual confounding.

conclusionsCOVID-19 is associated with high rates of AKI not fully explained by adjustment for known risk factors. This suggests the presence of mechanisms of AKI not accounted for in this analysis, which may include a direct effect of COVID-19 on the kidney or other unmeasured mediators. Future studies should evaluate the possible unique pathways by which COVID-19 may cause AKI.

Indexed as

Acute Kidney InjuryAgedCohort StudiesCOVID-19C-Reactive ProteinCreatinineDiureticsFemaleHospital MortalityHumansIntensive Care UnitsLength of StayMaleMiddle AgedProportional Hazards ModelsRenal DialysisC-Reactive ProteinCreatinineDiureticsVasoconstrictor Agentsacute kidney injury (AKI)Coronavirus disease 2019 (COVID-19)C-reactive protein (CRP)deathdialysisferritinhospital-acquired AKIhypotensioninflammationmortalityrenal recoveryrisk factorsserum creatininesevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)time-updated variables

Identifiers

PMID33422598
PMCPMC7791318
OpenAlexW3120233339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.